Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

Get in Touch

Our Locations

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Q²Solutions offers a TMB assay that utilizes a whole exome sequencing (WES) of tumor specimens for reliable quantification of TMB across various tumor indications.

Learn more about our TMB assay specifications and our comprehensive portfolio of genomic assays for immuno-oncology applications.

Download

Related Services & Solutions

Related Thought Leaders Insights

Scientific Poster

Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q² Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-SEQ with BioLegend. Describes CITE-seq performance expectations for...

Brochure

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

Factsheet

CNS Biomarkers

Rules-Based Medicine, a Q² Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...